Literature DB >> 23093646

Spontaneous regression of biopsy proven primary renal cell carcinoma: A case study.

Gurswinder Gary Jawanda1, Darrel Drachenberg.   

Abstract

Spontaneous regression of renal cell carcinoma (RCC) is a well-recognized and interesting phenomenon that is poorly understood and rarely documented. There are very few reported cases of spontaneously regressed primary RCC. We present a 63-year-old male with a biopsy-proven RCC that regressed with complete resolution of symptoms.

Entities:  

Year:  2012        PMID: 23093646      PMCID: PMC3478393          DOI: 10.5489/cuaj.11035

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  17 in total

1.  Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma.

Authors:  Alessandro Antonelli; Regina Tardanico; Piera Balzarini; Nicola Arrighi; Laura Perucchini; Tiziano Zanotelli; Alberto Cozzoli; Danilo Zani; Sergio Cosciani Cunico; Claudio Simeone
Journal:  Cancer Genet Cytogenet       Date:  2010-06

2.  Spontaneous regression of primary and metastatic renal cell carcinoma.

Authors:  M J Edwards; J A Anderson; J R Angel; J I Harty
Journal:  J Urol       Date:  1996-04       Impact factor: 7.450

3.  Spontaneous regression of cancer.

Authors:  T C Everson
Journal:  Ann N Y Acad Sci       Date:  1964-04-02       Impact factor: 5.691

4.  Natural history and staging of renal cell carcinoma.

Authors:  J M Holland
Journal:  CA Cancer J Clin       Date:  1975 May-Jun       Impact factor: 508.702

5.  Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group.

Authors:  M M Elhilali; M Gleave; Y Fradet; I Davis; P Venner; F Saad; L Klotz; R Moore; S Ernst; V Paton
Journal:  BJU Int       Date:  2000-10       Impact factor: 5.588

6.  Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes.

Authors:  F Jiang; J Richter; P Schraml; L Bubendorf; T Gasser; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

7.  Spontaneous regression of metastases of renal cancer: A report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature.

Authors:  D J Fairlamb
Journal:  Cancer       Date:  1981-04-15       Impact factor: 6.860

8.  Regression of established tumors and metastases by potent vascular endothelial growth factor blockade.

Authors:  Jianzhong Huang; Jason S Frischer; Anna Serur; Angela Kadenhe; Akiko Yokoi; Kimberly W McCrudden; Tamara New; Kathleen O'Toole; Stephanie Zabski; John S Rudge; Jocelyn Holash; George D Yancopoulos; Darrell J Yamashiro; Jessica J Kandel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-12       Impact factor: 11.205

9.  Immunotherapy for renal cell carcinoma.

Authors:  Momoe Itsumi; Katsunori Tatsugami
Journal:  Clin Dev Immunol       Date:  2011-01-03

10.  Small renal masses: incidental diagnosis, clinical symptoms, and prognostic factors.

Authors:  F M Sánchez-Martín; F Millán-Rodríguez; G Urdaneta-Pignalosa; J Rubio-Briones; H Villavicencio-Mavrich
Journal:  Adv Urol       Date:  2009-01-21
View more
  3 in total

1.  A rare case of spontaneous necrosis of primary renal cell carcinoma.

Authors:  Kyosuke Matsuzaki; Ryoichi Imamura; Toshichika Iwanishi; Masahiro Nakagawa; Go Tanigawa; Koichi Tsutahara; Kohki Shimazu; Hiroaki Fushimi; Toyonori Tsuzuki; Seiji Yamaguchi
Journal:  Can Urol Assoc J       Date:  2015 Jan-Feb       Impact factor: 1.862

Review 2.  Metastasis: Other Side of the Coin.

Authors:  Aftab Ahmad; Shoji Komai
Journal:  Front Oncol       Date:  2015-08-04       Impact factor: 6.244

Review 3.  Immune checkpoint inhibitors in renal cell carcinoma.

Authors:  Kirsty Ross; Rob J Jones
Journal:  Clin Sci (Lond)       Date:  2017-10-27       Impact factor: 6.124

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.